Key Takeaways for CVS Health Stock as of July 2026
- Eighteen buys, six outperforms and four holds leave CVS Health stock with a $108.81 mean target, just 4% above its $104.15 close, the tightest gap the stock has traded at in over a year.
- Still priced well below TIKR’s own model, CVS Health stock could reach $130.04 by December 2030, a 25% total return and 5% annualized rate over the next 4.5 years, according to TIKR’s mid case scenario.
- CVS Health stock trades cheap against normalized EPS, which the Street sees reaccelerating to 21% growth by the fourth quarter of 2026 after a rough 2025.
- On May 6, management raised 2026 adjusted EPS guidance to $7.30 through $7.50.
CVS Health Stock Nears 52-Week High After a Fifth Straight Earnings Beat
CVS Health (CVS), the pharmacy, insurance and Caremark benefits manager, closed at $104.15 on July 10, just below its 52-week high of $106.15, capping a rally that started with the company’s May 6 first quarter report. That print delivered adjusted earnings per share of $2.57, beating the consensus estimate of $2.20 by 37 cents, on revenue of $100.4 billion against expectations of $95.1 billion.
That beat came largely from the Health Care Benefits segment, where the medical benefit ratio, the share of premiums spent on medical claims, fell to 84.6%. That figure landed well below the 87.58% analysts had modeled and down from 87.3% a year earlier, as Aetna’s Medicare, Medicaid and commercial books all improved together.
The strength was enough for management to raise full year adjusted EPS guidance to $7.30 through $7.50, up from $7.00 through $7.20, and lift the revenue outlook to at least $405 billion. It marked CVS Health’s fifth consecutive quarterly beat since a rocky 2024 stretch that included several misses and a CEO change.
Addressing analyst questions about the durability of that earnings power, CFO Brian Newman said on the Q1 earnings call: “We remain confident in our ability to deliver mid-teens EPS CAGR through 2028.” That commitment, he added, holds even as Tennessee moves to restrict pharmacy benefit manager ownership of retail pharmacies, a law CVS is now contesting in federal court alongside a separate settlement process with the Federal Trade Commission over Caremark’s payment model.
Wall Street responded quickly to the print. Bernstein lifted its price target to $106 from $94 in May, citing progress in Aetna’s Medicare Advantage turnaround. Mizuho followed with a target of $110 from $102, pointing to a broader 2026 margin recovery across health insurers after a difficult three-year cycle.
CVS Health also declared a quarterly dividend of $0.665 per share on July 10, payable August 3 to shareholders of record July 23. The payout held steady as the company keeps working down leverage, which improved to 3.84 times debt to EBITDA in the first quarter, a level management flagged as ahead of its own targets.
Wall Street Turns Cautiously Bullish on CVS Health Stock After the Rally
Analyst sentiment on CVS Health stock remains firmly bullish, with 18 buy ratings, six outperforms and four holds among the analysts with no sell ratings on the stock. The mean price target of $109 compares with $80 a year earlier, but the gap to the $104 price has narrowed to just 4%, down from 116% in mid-2025.
That compression followed target hikes from Bernstein, to $106, and Mizuho, to $110, both citing progress in Aetna’s Medicare Advantage margin recovery already underway.
Wall Street Expects CVS Health Stock’s Normalized EPS to Reaccelerate Through 2027
CVS Health posted normalized EPS of $2.57 for the quarter ended March 31, 2026, up 14% from a year earlier and the highest quarterly figure the company has produced since mid-2025.
Analysts are expecting CVS’ normalized EPS of $1.83 for the June quarter and $1.71 for September, a modest 1% and 7% gain respectively, before a sharper 21% jump to $1.32 in the December quarter.
That momentum carries into fiscal 2027, with normalized EPS forecast to climb 8% to $2.76 in the March quarter and 15% to $2.11 by June, extending a recovery from the 8% decline posted back in December 2025 when reserve charges weighed on the government business.
Bulls point to the 21% growth analysts model for the December quarter as proof the turnaround has legs beyond a single strong print. Bears counter that normalized EPS still has to clear the $2.57 peak set in March 2026 again before the reacceleration fully re-rates CVS Health stock.
TIKR’s $130 Target on CVS Health Stock Holds if EPS Growth Reaccelerates as Guided
TIKR’s mid case model values CVS Health stock at $130.04 by December 2030, implying a 25% total return from the current price of $104.15, or 5% annualized over 4.5 years.
That annualized rate sits below the mid-teens EPS growth management says it can sustain through 2028, suggesting the market still prices CVS Health stock for a slower recovery than guidance implies even after the recent target hikes.
The target looks reachable given the fifth consecutive quarterly beat and the guidance raise to $7.30 through $7.50. That pace of execution would need to hold through the Medicare Advantage margin recovery Aetna has targeted for 2028 to fully close the gap to TIKR’s model.
The bigger swing factor is regulatory, not operational. Tennessee’s pharmacy ownership law and the pending FTC settlement over Caremark pricing both carry multi-year timelines, and management has said the business can absorb either outcome without derailing the EPS trajectory behind the $130.04 target.
Should You Invest in CVS Health Corporation?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up CVS Health Corporation stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track CVS Health Corporation alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze CVS stock on TIKR for Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
